Eli Lilly rises after lifting annual revenue view
LLY•Eli Lilly raised its full-year revenue forecast to $91 billion-$92 billion from $85 billion-$87 billion, while trimming its EPS view to $35-$36. Third-quarter EPS was $7.48, and shares rose 4.8% premarket.
1. Outlook and quarterly results
Eli Lilly raised its full-year revenue forecast to $91 billion-$92 billion from $85 billion-$87 billion and lowered its full-year EPS view to $35-$36 from $35.50-$36.50, citing research charges from recent acquisitions. Third-quarter EPS was $7.48, above the $6.26 estimate, with Mounjaro sales of $10.72 billion and Zepbound sales of $5.35 billion. Shares rose 4.8% to $1,350 premarket.
